Muzastotug (ADG126: masked anti-CTLA-4 Ab) — Clinical data readout
1H 2027
Enrollment into the randomized Phase 2 trial is well on-track, and results are expected in 1H 2027.Source filing
ADAG biotech catalysts & pipeline
ADAGENE INC · Data as of 2026-10-25